Reclast (zoledronic acid)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

DOSING:

Reclast is given intravenously over no less than 15 minutes. Administration of acetaminophen or ibuprofen may reduce infusion related reactions.

  • For treatment of postmenopausal osteoporosis, a single 5 mg infusion once a year is recommended.
  • For prevention of postmenopausal osteoporosis the recommended dose is 5 mg every two years.
  • Paget's disease of bone is treated with a single 5 mg infusion. Patients with Paget's disease should also receive 1500 mg of elemental calcium and 800 IU vitamin D daily, especially during the two weeks after the injection of Reclast.
  • For prevention or treatment of steroid-induced osteoporosis, the recommended dose is 5 mg once yearly.

DRUG INTERACTIONS:

  • Combining Reclast with aminoglycoside antibiotics such as gentamycin or loop diuretics such as furosemide (Lasix) or bumetanide (Bumex) may lead to reduced calcium in blood.
  • Reclast should be used with caution in patients who are taking drugs that affect kidney function because Reclast has been associated with reduced kidney function.
  • Since Reclast contains the same active ingredient as zoledronic acid (Zometa), patients treated with Zometa should not receive Reclast.

PREGNANCY AND BREASTFEEDING SAFETY:

  • Reclast should not be administered to pregnant women. Women of childbearing age should be advised to use a reliable method of birth control.
  • It is not known whether Reclast is excreted in human milk. Since many drugs are excreted in human milk, and Reclast binds to bone long-term, Reclast should not be administered to nursing women.

PREPARATIONS: Solution: 5 mg/100 ml

STORAGE:

  • Unopened bottles should be kept at room temperature 15 C-30 C (59 F-86 F).
  • Opened bottles of solution are stable for 24 hours at 2 C-8 C (36 F-46 F).
Medically Reviewed by a Doctor on 9/13/2016

Quick GuideWhat Is Osteoporosis? Treatment, Symptoms, Medication

What Is Osteoporosis? Treatment, Symptoms, Medication
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Women's Health Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors